Kuros Biosciences Kuros Biosciences is a biopharmaceutical company that engages in the development of biopharmaceutical products for tissue repair and bone regeneration. | ![]() Merus Merus is a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics with the goal of treating and potentially curing cancer patients. | ![]() Dermavant Sciences Dermavant Sciences, a clinical-stage biopharmaceutical company, develops and commercializes therapeutics in medical dermatology. | |
Founding Date | Founding Date 2000 | Founding Date 2003 | Founding Date 2016 |
Type | Type Public | Type Public | Type Subsidiary |
Tags | |||
Locations | Locations Zürich, CH HQ Bilthoven, NL Boston, US | Locations Utrecht, NL HQ Cambridge, US | Locations Long Beach, US HQ Basel, CH Durham, US Morrisville, US New York, US Phoenix, US |
Employees | Employees 122 | Employees 260 | Employees 2228% decrease |
Financial | |||
Revenue (est.) | Revenue (est.) $146.1m (FY, 2025) | Revenue (est.) $36.1m (FY, 2024) | Revenue (est.) N/A |
Cost of goods | Cost of goods $16.5m (FY, 2025) | Cost of goods N/A | Cost of goods N/A |
Gross profit | Gross profit $129.7m (FY, 2025) | Gross profit $36.1m (FY, 2024) | Gross profit N/A |
Net income | Net income $2.5m (FY, 2025) | Net income ($215.3m) (FY, 2024) | Net income ($255.3m) (FY, 2019) |
Funding | |||
Total funding raised | Total funding raised N/A | Total funding raised $ 149.3m | Total funding raised $ 200m |

Merus is a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics with the goal of treating and potentially curing cancer patients.
View company
Dermavant Sciences, a clinical-stage biopharmaceutical company, develops and commercializes therapeutics in medical dermatology.
View company